The Ask Suicide-Screening Questions (ASQ) tool is a brief validated tool for use among both youth and adults. The Joint Commission approves the use of the ASQ for all ages. Additional materials to help with suicide risk screening implementation are available in The Ask Suicide-Screening Questions (ASQ) Toolkit, a free resource for use in medical settings (emergency department, inpatient medical/surgical units, outpatient clinics/primary care) that can help providers successfully identify individuals at risk for suicide. The ASQ toolkit consists of youth and adult versions as some of the materials take into account developmental considerations.
Dr. Phonexay provides strong acupuncture experience from mental/physical/energetic/spiritual care as she truly provides comprehensive holistic care to her patients within the integrative space of Rebel Med NW, working with local physical therapists, mental health providers, and traditional medical teams.
An Interview with Lisa Ballard, Primary Therapist
In a 2011 interview with Ms. Magazine, hooks said, "I really believe that love as a political transformative force in our society can change the world. It's been love that motivates people to the most deep and profound change.
"It was just something I tried one night. I was just sitting at the typewriter, and I thought, 'Well, let me give this a try. What would it be like if you could get a vampire to tell you what his experiences were, like an interview with the vampire?'"
In a 2019 interview with Golf Digest, Elder recalled his initial round at Augusta: "Most of the staff was Black, and on Friday, they left their duties to line the 18th fairway as I walked toward the green. The other patrons cleared the way for them to come to the front, and they were instantly recognizable by their uniforms. This took planning on the part of the employees and moved me very deeply. I couldn't hold back the tears. One club employee shouted in this booming voice that rose above the applause, 'Thank you for coming, Mr. Elder!' Other employees, taking his cue, shouted the same thing. Of all the acknowledgements of what I had accomplished by getting there, this one meant the most."
In a 2021 NPR interview, Bricusse ruminated on the lasting appear of his "Willy Wonka" song, "Pure Imagination": "It's a good thought for people, especially young people, to carry with them through life. You'll be free if you truly wish to be, at the end is, to me, the most important line in the film. It's a reflective thought on how to make a life work."
In a 2013 interview with the Western Carolina Journal, Patten recounted the rough, early years of his career (being cut loose from the Canadian Football League, ignored during the 1996 NFL draft, and, after a year in the Arena Football League, being picked up, then dropped by the Giants), and how he finally found his footing with Brady and the Patriots.
Director of the Center for Health Communication , Stan Richards School of Advertising and Public Relations , Moody College of Communication +1 512 348 8490, mackert@utexas.edu Dr. Mackert's primary research interest is telemedicine, the provision of healthcare from a distance via telecommunication technology. He is also interested in health communication, with a particular focus on how trust plays a role in the communication process. Other interests include health literacy and online communities.
Point-of-care tests for chlamydia (CT) and gonorrhoea (NG) could increase the uptake and timeliness of testing and treatment, contribute to improved disease control and reduce reproductive morbidity. The GeneXpert (Xpert CT/NG assay), suited to use at the point-of-care, is being used in the TTANGO randomised controlled trial (RCT) in 12 remote Australian health services with a high burden of sexually transmissible infections (STIs). This represents the first ever routine use of a molecular point-of-care diagnostic for STIs in primary care. The purpose of this study was to explore the acceptability of the GeneXpert to primary care staff in remote Australia.
In-depth qualitative interviews were conducted with 16 staff (registered or enrolled nurses and Aboriginal Health Workers/Practitioners) trained and experienced with GeneXpert testing. Interviews were digitally-recorded and transcribed verbatim prior to content analysis.
Data Availability: Data cannot be made publicly available as study participants consented to interviews with the understanding that their data would remain anonymous and confidential. Study data are available upon request via the Sexual Health Program co-ordinator at the Kirby Institute ( -program/sexual-health-program/about-program). Requests may be sent to: jcostello@kirby.unsw.edu.au.
The GeneXpert CT/NG assay is being utilised in the TTANGO (Test, Treat, ANd GO) trial.[3] TTANGO is a cross-over cluster randomised controlled trial underway in 12 remote Australian primary health care services in communities with a predominantly Aboriginal and Torres Strait Islander (hereafter referred to as Aboriginal) population. To our knowledge the trial represents the first use of a point-of-care molecular diagnostic test for STIs in a primary health care setting anywhere in the world.[3] GeneXpert platforms have been used for other infectious diseases, such as tuberculosis, but largely in laboratory settings.[4]
Provision of accurate testing and timely treatment through primary care services is a key STI control and prevention strategy. Point-of-care tests for CT and NG have the potential to increase the uptake and timeliness of testing and treatment and reduce the average duration of infectiousness,[5] thereby contributing to improved STI control in remote Australia and similar settings elsewhere. As utilisation of these new molecular point-of-care tests for CT/NG is a substantial change to clinical practice in these remote areas, and generally across the world, the TTANGO trial included comprehensive evaluation of the clinical, operational and cost-effectiveness of CT/NG point-of-care testing as well as its acceptability to health care staff and patients.
There were also some minor points of dissatisfaction raised by staff interviewed. The lack of automated data flow between the GeneXpert and the patient management system and other concerns relating to connectivity will be addressed before wider implementation of the GeneXpert system in Australia. In addition, it will be important to work with implementing staff to ensure greater clarity around patient and sample identifiers used in the GeneXpert device; this issue could readily be resolved by modifying the software data fields and including additional resource material on this subject in future training materials.
This is the first study to explore acceptability of the GeneXpert CT/NG in remote primary care in Australia or elsewhere. The main strength of this study is that we used qualitative methods, which are well suited to open-ended enquiry or exploratory research where little is known about the issue under study. Our study also has several limitations. The small sample size and non-random nature of the sampling strategy limit the generalisability of the results, however we did interview key staff involved in GeneXpert testing in seven of the 12 services. The interviewer was not completely independent of trial implementation; however there is no reason to believe that her relationship to the project affected responses. At this stage we are unable to comment in detail on whether there were acceptability issues beyond the users themselves.
When a nurse Joan used to work with asks for her help in finding their missing acquaintance, the woman's trail leads Sherlock and Joan to an illegal human drug trial of a time-dilating substance known as EZM-77. Five test subjects were injected with varying dosages. The higher the dose the madder they went (one killed the missing nurse, who administered the drug) and they die or are murdered. Carlisle, on the lowest dose, survives and his interview leads to the name of a mysterious company called Purgatorium, which paid the human guinea pigs $150,000 up front and promised the same amount every year. The drug's inventor, Dwyer Kirk, takes full responsibility for the deaths, refusing to reveal who funded him. Sherlock identifies the sponsor - James Connaughton, who paid for Kirk's education and gave his aunt a stipend to help raise him. When Connaughton learned he was dying, he approached Kirk, who agreed to try to develop a "pharmaceutical fountain of youth" so that its time-dilating properties would make his last days feel like years. The trial subjects were executed to cover it up, but Connaughton refuses to confess or co-operate. Sherlock and Watson appeal instead to his new nurse, Brett Won. Shown photos of the dead victims and asked to give their families closure, Won connects Connaughton directly with Purgatorium and with the two hitmen he hired to murder the test subjects. However, when the police come for Connaughton, Sherlocks finds the man non-responsive; he has injected himself with EZM-77, hoping to "extend" what little time he has left to live.
Sherlock and Joan investigate two murders in which the killer leaves envelopes of cash on the victims equating to their "worth". The probe leads the two to investigate an airline crash which killed over 80 people and the amount that each would receive as wrongful death compensation according to an equation formulated by attorney Arlen Schrader. When Dana Powell (Alicia Witt), the wife of one of the crash victims, reports being shot at from her back yard, Sherlock becomes suspicious, as the first two shootings were at short range. Powell gives a seemingly tone-deaf television interview, which forces the airline to drop its method of calculation to making the same flat payment to each next-of-kin. This is puzzling, as Powell's husband was a highly successful broker. Then they discover that the husband had a fatal disease, with only a few months to live. The police to obtain a search warrant for her mansion, where they find incriminating evidence. 2ff7e9595c
Comments